FDA SETS ASIDE JULY 28 FOR ADDITIONAL ZOVIRAX Rx-TO-OTC SWITCH REVIEW; DUAL Rx/OTC STATUS SUGGESTED AS WAY OF KEEPING INSURANCE COVERAGE BY AMWA
Executive Summary
Burroughs Wellcome's antiviral Zovirax has been allotted additional time by FDA for a July 28 review of its potential Rx- to-OTC switch by the agency's Nonprescription Drugs Advisory Committee and the Antiviral Drugs Advisory Committee, according to a tentative list of advisory committee meeting dates.